Introduction
============

Diabetes mellitus (DM) poses a major threat towards global health. At present, the number of patients with diabetes has reached 180 million worldwide, of which type 2 diabetes (T2DM) accounts for \>90% of cases ([@b1-mmr-22-04-3073]). Among numerous factors, insulin resistance serves an important role in the development of T2DM ([@b2-mmr-22-04-3073]). Previous studies have revealed that T2DM not only induces physical symptoms, cell functional damage and self-management capacity decline, but also results in uncontrolled blood glucose and cardiovascular complications, consequently increasing mortality ([@b3-mmr-22-04-3073],[@b4-mmr-22-04-3073]). It has been reported that the severity of T2DM is strongly associated with the control of blood glucose in patients with T2DM ([@b5-mmr-22-04-3073]). As it is important to improve the prognosis of T2DM patients, treatment with long-term use of antidepressant drugs is essential.

Fluoxetine, a selective 5-hydroxytryptamine (5-HT) reuptake inhibitor, is the most commonly used drug for the treatment of patients with T2DM ([@b6-mmr-22-04-3073]). A recent study revealed that fluoxetine hydrochloride can improve glucose tolerance and insulin resistance ([@b7-mmr-22-04-3073]). Ghaeli *et al* ([@b8-mmr-22-04-3073]) has reported that non-diabetic patients orally administered fluoxetine exhibit reduced levels of fasting blood glucose. In addition, a meta-analysis based on five large-scale clinical trials has indicated that fasting blood glucose and triglycerides are significantly decreased in T2DM patients treated with fluoxetine hydrochloride compared with a placebo group ([@b9-mmr-22-04-3073],[@b10-mmr-22-04-3073]). In addition, fluoxetine hydrochloride can increase insulin sensitivity ([@b11-mmr-22-04-3073]--[@b13-mmr-22-04-3073]). These results suggest that fluoxetine may improve insulin resistance and the therapeutic outcome of non-depressed patients with T2DM; however, the roles of fluoxetine in reducing blood glucose, weight loss and improving insulin resistance, as well as the underlying mechanisms remain unknown.

The liver is the major organ that produces glucose via gluconeogenesis and glycogenolysis ([@b13-mmr-22-04-3073]). A previous study has revealed that at the early stage of hepatosteatosis, patients are often unaware of their impaired insulin sensitivity ([@b14-mmr-22-04-3073]); the functions of the liver in the insulin-resistant state remain unknown. The phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) signaling pathway serves an important role in glucose synthesis and uptake and gluconeogenesis in the liver; the PI3K-AKT pathway also promotes adipose formation by stimulating insulin and regulating the functions of fat ([@b15-mmr-22-04-3073],[@b16-mmr-22-04-3073]). In the present study, the effects of fluoxetine on fasting blood sugar and glucolipid metabolism in diabetic rats were investigated.

Materials and methods
=====================

### Animal models and experimental designs

The present study was conducted using male Sprague-Dawley rats (n=24; age, 6-weeks; weight, 180--220 g), provided by the Model Animal Research Institute of Nanjing University (Nanjing, China). The rats were divided into four groups: i) Control; ii) DM; iii) DM +20 mg/kg fluoxetine (H-fluoxetine); and iv) DM +40 mg/kg fluoxetine (L-fluoxetine). The mice were maintained under standard laboratory conditions under a 12 h light/dark cycle with adequate temperature (25°C) and humidity (45--55%), and free access to food and water. The present study was approved by the Ethics Committee of Nanjing Medical University (Nanjing, China).

The rats were treated with streptozotocin (STZ; 60 mg kg) in citrate buffer (pH 4.5) via an intraperitoneal injection within 15 min of dissolution. The control group was treated with citrate buffer alone. After 3 weeks of stimulation with STZ, rats with a random blood glucose value of 300 mg/dl were considered to have STZ-induced diabetes. Then, STZ-treated rats were injected intraperitoneally with 20 or 40 mg/kg fluoxetine (Sun Pharmaceutical Industries Ltd., Mumbai, India) once a day for 21 days.

### Determination of glucose and glucolipid metabolism

Blood samples were obtained from the rats and centrifuged at 1,509 × g for 15 min at 4°C. Then, the sera were used to evaluate the levels of total cholesterol (TC; cat. no. A111-1), triglyceride (TG; cat. no. A110-1) and fasting blood glucose (FBG; cat. no. F006-1-1) using enzymatic assays (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer\'s protocols. The fasting insulin (FINS) level was estimated using a ELISA kit (cat. no. JCSW2610) provided by Shanghai Jichun Industrial Co., Ltd. Insulin resistance was estimated using a homeostasis model, as described previously ([@b17-mmr-22-04-3073]).

### Insulin tolerance test (ITT) and intraperitoneal glucose tolerance test (IPGTT)

Rats were fasted overnight and then anesthetized; insulin (0.5 UI/kg) was injected intravenously into the tail vein. Blood collection were performed via the tail vein, and the concentration of blood glucose was evaluated at 0, 15, 30, 60, 90 and 120 min using a Biosen glucose analyzer (EKF-diagnostic GmbH). Prior to the IPGTT, rats were fasted overnight and anesthetized, and blood samples were obtained. Then, 1 g/kg glucose was injected intraperitoneally. Blood samples were collected and glucose levels were determined at 0, 15, 30, 60, 90 and 120 min. Blood glucose was measured according to the manufacturer\'s protocol (Biosen glucose analyzer; EKF-diagnostic GmbH).

### Pathological analysis

Following sacrifice, the liver tissues of rats were obtained and fixed using 4% paraformaldehyde for 24 h at 25°C, and then dehydrated, embedded in paraffin and sliced into sections of 4 µm thickness, which were subjected to hematoxylin and eosin staining for 1 min at 25°C. The overall histological features (magnification, ×200) were observed and recorded via a light microscope (Olympus Corporation, Tokyo, Japan); five fields in each image were analyzed.

### Oil Red O staining

The liver tissues of rats were embedded in optimal cutting temperature compound (Sakura Finetek USA, Inc.), snap-frozen and sliced into 5-μm sections, which were stained for 1 h at 25°C using an Oil Red O staining kit (Nanjing KeyGen Biotech Co., Ltd.). The staining (magnification, ×200) was visualized by light microscopy (Olympus Corporation). The percentage of red staining in five fields of each image was determined using Image Pro Plus 6.0 (Media Cybernetics, Inc.).

### Immunohistochemistry staining

The method of immunohistochemistry was performed as previously described ([@b18-mmr-22-04-3073]). The liver tissues of rats were fixed using 4% paraformaldehyde for 30 min at 25°C, and then dehydrated, embedded in paraffin and sliced into sections of 4 µm thickness. Sections were deparaffinized with xylene and were incubated with primary antibodies against phosphorylated (p)-PI3K (1:500; cat. no. ab182651; Abcam, Cambridge, MA, USA), PI3K (1:500; cat. no. ab135253; Abcam), p-Thr308-AKT (p-AKT; 1:500; cat. no. ab8933; Abcam), and AKT (1:500; cat. no. ab8805; Abcam) overnight at 4°C, followed by incubation with a horseradish peroxidase-conjugated secondary antibody (1:2,000; cat. nos. ab214880 and ab97040; Abcam) for 2 h at 25°C. Then, the sections were incubated using a 3,3′-diaminobenzidine kit (Vector Laboratories, Inc.) according to the manufacturer\'s protocols. The expression of each protein was observed by light microscopy (Olympus Corporation); five fields in each image were analyzed. The findings were analyzed determined using Image Pro Plus 6.0.

### Cell culture and treatment

The BRL-3A rat normal liver cell line was purchased from American Type Culture Collection. Cells were cultured in Dulbecco\'s modified Eagle\'s medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in an atmosphere containing 5% CO~2~. Cells were maintained in high glucose (30 mM) in the presence or absence of fluoxetine (30 µM; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) or LY294002 (30 µM; Sigma-Aldrich) at 37°C for 24 h. Subsequently, the expression levels of associated proteins were detected.

### Western blotting

Total proteins were extracted from liver tissues or BRL-3A cells using different methods as previously described ([@b14-mmr-22-04-3073],[@b15-mmr-22-04-3073]). The proteins were quantified using the bicinchoninic acid assay (Applygen Technologies, Inc.). The samples (30 µg) were separated using 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes, which were then blocked with skimmed milk for 1 h at 25°C and incubated at 4°C overnight with primary antibodies as follows: GAPDH (1:5,000; cat. no. ab9485; Abcam), glycogen synthase kinase 3β (GSK-3β; 1:2,000; cat. no. ab93926; Abcam), glucose-6 phosphatase catalytic subunit (G6PC; 1:2,000; cat. no. ab133964; Abcam), phosphoenolpyruvate carboxykinase (PEPCK; 1:2,000; cat. no. ab70359; Abcam), forkhead box protein O1 (FOXO1; 1:2,000; cat. no. ab52857; Abcam), sterol regulatory element-binding protein 1-c (SREBP1-c; 1:2,000; cat. no. ab28481; Abcam), peroxisome proliferator-activated receptor γ (PPARγ; 1:2,000; cat. no. ab59256; Abcam), fatty acid synthase (FAS; 1:2,000; cat. no. ab82419; Abcam), lipoprotein lipase (LPL; 1:2,000; cat. no. ab21356; Abcam), PI3K (1:2,000; cat. no. ab135253; Abcam), AKT (1:2,000; cat. no. ab8805; Abcam), p-PI3K (1:2,000; cat. no. ab182651; Abcam) and p-AKT (1:2,000; cat. no. ab8933; Abcam). The membranes were washed in tris-buffered saline with 0.05% Tween-20 for three times and incubated with horseradish peroxidase-conjugated secondary antibody (1:2,000; cat. nos. ab97040 and ab99697; Abcam) for 2 h at 25°C. The bands were visualized by using an enhanced chemiluminescence protein detection kit (Beyotime Institute of Biotechnology). GAPDH was used to normalize protein expression. Densitometry analysis was performed using ImageJ 6.0 software (National Institutes of Health) and the experiment was repeated at least three times.

### Statistical analysis

Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc.). Each experiment was repeated at least three times and data were presented as the mean ± standard deviation. When only two groups were compared, a Student\'s t-test was used. One-way ANOVA followed by Tukey\'s test was applied to compare differences between multiple groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Effects of the treatment with fluoxetine on blood glucose in rats with STZ-induced diabetes

FBG in rats treated with STZ or fluoxetine were examined. As presented in [Fig. 1A](#f1-mmr-22-04-3073){ref-type="fig"}, the levels of FBG were significantly increased in diabetic rats compared with the control (P\<0.05); however, the levels were significantly reduced following the treatment with fluoxetine. In addition, the levels of random blood glucose were determined, and similar effects were observed ([Fig. 1B](#f1-mmr-22-04-3073){ref-type="fig"}). Furthermore, the levels of FINS in rats were evaluated. The levels of FINS were significantly increased in diabetic rats compared with the control (P\<0.05), while significantly decreased levels were observed in the fluoxetine-treated groups compared with the DM group ([Fig. 1C](#f1-mmr-22-04-3073){ref-type="fig"}). Additionally, the insulin resistance index was evaluated. The results revealed that the resistance index was significantly increased in diabetic rats compared with normal rats (P\<0.05); however, the index was significantly reduced by treatment with fluoxetine ([Fig. 1D](#f1-mmr-22-04-3073){ref-type="fig"}).

IPGTT and ITT were performed to investigate the function of fluoxetine in rats. The results revealed that fluoxetine treatment significantly improved insulin and glucose tolerance ([Fig. 1E](#f1-mmr-22-04-3073){ref-type="fig"}). In addition, the expression levels of glucose metabolism-associated proteins GSK-3β, G6PC, PEPCK and FOXO1 were significantly increased in diabetic rats compared with the control (P\<0.05), whereas the effects of STZ-induced diabetes were significantly abolished following treatment with fluoxetine ([Fig. 1F](#f1-mmr-22-04-3073){ref-type="fig"}).

### Effects of fluoxetine on lipid metabolism in rats with STZ-induced diabetes

Numerous pathways are involved in the development of diabetes, including insulin secretion, insulin signaling, glycolysis and lipid metabolism ([@b19-mmr-22-04-3073],[@b17-mmr-22-04-3073]). To investigate the extent of lipid metabolism, the expression levels of associated proteins were evaluated in rats. As presented in [Fig. 2A and B](#f2-mmr-22-04-3073){ref-type="fig"}, the levels of TG and TC in sera were significantly increased in diabetic rats compared with the control (P\<0.05), while the effects were abolished in the fluoxetine-treated groups. In addition, the expression levels of PPARγ, FAS and LPL were significantly downregulated in diabetic rats (P\<0.05), whereas SREBP1-c was upregulated in diabetic rats compared with the control; however, the expression profile of the proteins was reversed following treatment with fluoxetine ([Fig. 2C](#f2-mmr-22-04-3073){ref-type="fig"}).

### Fluoxetine attenuates liver morphology damage and lipid accumulation in rats with STZ-induced diabetes

To investigate the underlying mechanisms of fluoxetine on insulin resistance, the present study selected the liver for analysis as it participates in glucose and lipid metabolism ([@b20-mmr-22-04-3073]). Thus, liver morphology and lipid accumulation were evaluated. As presented in [Fig. 3A](#f3-mmr-22-04-3073){ref-type="fig"}, liver cells were disorderly arranged in diabetic rats compared with the control; cell swelling, sparse cytoplasm and necrosis of liver cells were also observed in diabetic rats. Fewer disordered liver cells and reduced necrosis were detected in fluoxetine-treated rats. Lipid accumulation in liver sections was indicated by Oil Red O staining. The lipid content was increased in diabetic rats, whereas treatment with fluoxetine notably decreased the lipid content ([Fig. 3B](#f3-mmr-22-04-3073){ref-type="fig"}).

### Fluoxetine affects the PI3K-AKT signaling pathway in in rats with STZ-induced diabetes

It has previously been indicated that the PI3K-AKT signaling pathway serves a vital role in the liver; dysregulated signaling can lead to impaired glucolipid metabolism, resulting in liver insulin resistance ([@b21-mmr-22-04-3073]). The expression levels of p-PI3K and p-AKT were notably upregulated in diabetic rats compared with the control ([Fig. 4A](#f4-mmr-22-04-3073){ref-type="fig"}); however, reduced expression of p-PI3K and p-AKT was observed in diabetic rats following treatment with fluoxetine. The expression levels of AKT in the diabetic rats appeared notably unchanged, whereas PI3K expression was markedly increased. Treatment with fluoxetine revealed a marked increase in the expression of AKT and reduced PI3K expression. The ratios of p-PI3K/PI3K and p-AKT/AKT were significantly increased in diabetic rats compared with the control (P\<0.05; [Fig. 4B](#f4-mmr-22-04-3073){ref-type="fig"}); the ratios were significantly reduced following treatment with fluoxetine compared with in diabetic rats.

### LY294002 enhances the effects of fluoxetine on glucose and lipid metabolism

LY294002 is a specific inhibitor of PI3K, which suppresses the PI3K-AKT signaling pathway. To investigate the molecular mechanisms of fluoxetine on insulin resistance, BRL-3A cells were maintained in high glucose in the presence or absence of fluoxetine or LY294002. The expression levels of glucose metabolism-associated proteins, including GSK-3β, G6PC, PEPCK and FOXO1 were evaluated by western blotting. The protein expression levels, including GSK-3β, G6PC, PEPCK and FOXO1, were significantly increased in the DM group compared with in the control group, while expression was significantly reduced following the treatment with fluoxetine and LY294002 (P\<0.05; [Fig. 5A](#f5-mmr-22-04-3073){ref-type="fig"}). Besides, the expression levels of PPARγ and FAS were significantly decreased in the DM group compared with in the control group, whereas treatment with fluoxetine and LY294002 reversed these effects. Additionally, the ratios of p-AKT/AKT and p-PI3K/PI3K were significantly increased in the DM group compared with in the control group, whereas treatment with fluoxetine and LY294002 significantly decreased the protein levels of p-PI3K and p-AKT compared with in the DM group ([Fig. 5B](#f5-mmr-22-04-3073){ref-type="fig"}).

Discussion
==========

Diabetes is a chronic disease, and there is no effective treatment for diabetes apart from long-term diet control or the administration of insulin ([@b22-mmr-22-04-3073],[@b23-mmr-22-04-3073]). Long-term treatment serves a vital role in the treatment of diabetes ([@b24-mmr-22-04-3073]). T2DM can result in disorders of glycolipid metabolism and insulin resistance ([@b25-mmr-22-04-3073],[@b26-mmr-22-04-3073]), consequently leading to increased blood glucose and weight loss, which lead to adverse effects in patients with T2DM.

Selective serotonin reuptake inhibitors are antidepressants used for the treatment of anxiety disorders ([@b27-mmr-22-04-3073]). Fluoxetine, a selective 5-HT reuptake inhibitor, is the most commonly used drug to treat patients with T2DM ([@b28-mmr-22-04-3073],[@b29-mmr-22-04-3073]). Ghaeli *et al* ([@b8-mmr-22-04-3073]), reported that oral administration of fluoxetine in non-diabetic patients decreased the levels of FBG. In addition, a meta-analysis based on five large-scale clinical trials revealed that the levels of FBG and TG were significantly reduced in patients with T2DM following treatment with fluoxetine hydrochloride compared with a placebo ([@b9-mmr-22-04-3073],[@b10-mmr-22-04-3073]); however, the effects of fluoxetine on lipid metabolism and the underlying mechanisms remain unknown. In the present study, STZ-induced T2DM rats were used to mimic the metabolic characteristics of T2DM as reported previously ([@b30-mmr-22-04-3073]); the effects of fluoxetine on glucose and lipid metabolism were investigated ([@b31-mmr-22-04-3073]). Additionally, the levels of FBG and random glucose were significantly decreased in STZ-induced T2DM rats following treatment with fluoxetine hydrochloride in the present study, indicating that fluoxetine may reduce hyperglycemia and increase insulin sensitivity; the molecular mechanisms may be associated with muscle glycogen synthesis ([@b32-mmr-22-04-3073]). Park *et al* ([@b33-mmr-22-04-3073]), revealed that 90% pancreatic resection increased glucose clearance and decreased blood insulin levels following 8 weeks of fluoxetine treatment. Tembhurne *et al* ([@b34-mmr-22-04-3073]) reported that fluoxetine reduced the levels of FBG and improved glucose tolerance in rats with STZ-induced diabetes. In summary, fluoxetine may reduce blood glucose and body weight loss, and improve insulin resistance; however, the underlying molecular mechanisms remain unknown.

The liver participates in glucose and lipid metabolism ([@b35-mmr-22-04-3073],[@b36-mmr-22-04-3073]). In the present study, liver tissue morphology and lipid accumulation were investigated, and the potential roles of fluoxetine were determined. Liver cells were disorderly arranged; cell swelling, sparse cytoplasm and necrosis of liver cells were observed in diabetic rats. A reduction in the number of aberrant liver cells and necrosis were detected in fluoxetine-treated rats. The present study hypothesized that lipid accumulation in the liver may increase insulin resistance and affect glucose metabolism. Numerous genes serve crucial roles in the regulation of hepatic glucose and lipid metabolism. For instance, G6PC, PEPCK and GSK-3β are involved in hepatic carbohydrate metabolism ([@b37-mmr-22-04-3073]--[@b39-mmr-22-04-3073]). FAS and LPL are associated with lipid metabolism ([@b40-mmr-22-04-3073],[@b41-mmr-22-04-3073]). In addition, various studies investigated the association between fluoxetine and lipid metabolism in liver toxicity ([@b20-mmr-22-04-3073],[@b42-mmr-22-04-3073]); PPARγ may be involved in these processes ([@b43-mmr-22-04-3073]). In the present study, the results revealed that GSK-3β, G6PC, PEPCK and FOXO1 were upregulated in diabetic rats, whereas the effects were inhibited following treatment with fluoxetine. Additionally, the expression levels of PPARγ, FAS and LPL were downregulated, whereas SREBP1-c was upregulated in diabetic rats compared with the control; however, the expression profile of these proteins were reversed following fluoxetine treatment.

Previous studies revealed that the PI3K/AKT signaling pathway served a critical role in the liver, and disrupted signaling may lead to impaired glycolipid metabolism and result in insulin resistance of the liver ([@b44-mmr-22-04-3073],[@b45-mmr-22-04-3073]). In the present study, fluoxetine inhibited the phosphorylation of PI3K and AKT, and suppressed the PI3K/AKT signaling pathway. The activation of this signaling pathway can alter glucose and lipid metabolism in the liver, subsequently enhancing the sensitivity to insulin and improving insulin resistance ([@b46-mmr-22-04-3073]). In the present study, primary hepatocytes of type 2 diabetic rats were isolated and treated with fluoxetine and PI3K inhibitor LY294002 *in vitro*. The results revealed that LY294002 downregulated the expression of glucose metabolism-associated proteins in rats with STZ-induced diabetes. In summary, the results of the present study demonstrated that fluoxetine treatment may improve the symptoms of diabetes via regulating the PI3K-AKT signaling pathway.

Not applicable.

Funding
=======

The research was supported by the Medical Science and Technology Development Foundation, Nanjing Department of Health (grant no. YKK15055).

Availability of data and materials
==================================

All data generated or analyzed during this study are included in this published article.

Authors\' contributions
=======================

HY, QC and NZ designed the experiments. XX, PZ and DS performed the experiments. YZ made substantial contributions in analyzing the data. HY drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

The present study was approved by the Ethics Committee at Nanjing Medical University (Nanjing, China).

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Effects of fluoxetine treatment on blood glucose in rats with STZ-induced diabetes. (A) Fluoxetine reduced the levels of fasting blood glucose rats with STZ-induced diabetes. (B) Effects of fluoxetine on the levels of random blood glucose in rats with STZ-induced diabetes. (C) Fluoxetine downregulated the levels of FIN in rats with STZ-induced diabetes. (D) Effects of fluoxetine on the insulin resistance index in rats with STZ-induced diabetes. (E) Fluoxetine improved intraperitoneal glucose tolerance and insulin tolerance in rats with STZ-induced diabetes. (F) Effects of fluoxetine on the expression levels of glucose metabolism-associated proteins in rats with STZ-induced diabetes. ^\#^P\<0.05 vs. the control group. \*P\<0.05 vs. the DM group. DM, diabetes mellitus; FOXO1, forkhead box protein O1; G6PC, glucose-6 phosphatase catalytic subunit; GSK-3β, glycogen synthase kinase 3β; H-fluoxetine, 20 mg/kg fluoxetine; L-fluoxetine, 40 mg/kg fluoxetine; PEPCK, phosphoenolpyruvate carboxykinase; STZ, streptozotocin.](MMR-22-04-3073-g00){#f1-mmr-22-04-3073}

![Effects of fluoxetine on lipid metabolism in rats with STZ-induced diabetes. (A) Fluoxetine suppressed the levels of triglyceride in rats with STZ-induced diabetes. (B) Fluoxetine reduced the levels of total cholesterol in rats with STZ-induced diabetes. (C) Effects of fluoxetine on the expression levels of glucose metabolism-associated proteins in rats with STZ-induced diabetes. ^\#^P\<0.05 vs. the control group. \*P\<0.05 vs. the DM group. DM, diabetes mellitus; FAS, fatty acid synthase; H-fluoxetine, 20 mg/kg fluoxetine; L-fluoxetine, 40 mg/kg fluoxetine; LPL, lipoprotein lipase; PPARγ, peroxisome proliferator-activated receptor γ; SREBP-1c, sterol regulatory element-binding protein 1-c; STZ, streptozotocin.](MMR-22-04-3073-g01){#f2-mmr-22-04-3073}

![Fluoxetine attenuates liver morphology damage and lipid accumulation in rats with STZ-induced diabetes. (A) Hematoxylin and eosin staining revealed cellular morphology in diabetic liver tissues. (B) Oil Red O staining indicated lipid accumulation in diabetic rats. Scale bar, 100 μm. DM, diabetes mellitus; H-fluoxetine, 20 mg/kg fluoxetine; L-fluoxetine, 40 mg/kg fluoxetine; STZ, streptozotocin.](MMR-22-04-3073-g02){#f3-mmr-22-04-3073}

![Fluoxetine affects the PI3K-AKT signaling pathway in rats with STZ-induced diabetes. (A) Immunohistochemistry staining was used to analyze the proteins associated with PI3K-AKT pathway. Scale bar, 100 μm. (B) Western blotting revealed the expression levels of proteins involved in the PI3K-AKT signaling pathway; the ratio of p-AKT/AKT and p-PI3K/PI3K are presented. ^\#^P\<0.05 vs. the control group. \*P\<0.05 vs. the DM group. DM, diabetes mellitus; H-fluoxetine, 20 mg/kg fluoxetine; L-fluoxetine, 40 mg/kg fluoxetine; PI3K-AKT, phosphatidylinositol 3-kinase-protein kinase B; p-, phosphorylated; STZ, streptozotocin.](MMR-22-04-3073-g03){#f4-mmr-22-04-3073}

![LY294002 enhances the effects of fluoxetine on glucose and lipid metabolism. (A) Western blotting revealed the expression levels of glucose metabolism-associated proteins. (B) Western blotting indicated the expression levels of proteins involved in the PI3K-AKT signaling pathway. ^\#^P\<0.05 vs. the control group. \*P\<0.05 vs. the DM group. DM, diabetes mellitus; GSK-3β, glycogen synthase kinase 3β; G6PC, guocose-6 phosphatase catalytic subunit; H-fluoxetine, 20 mg/kg fluoxetine; FAS, fatty acid synthase; FOXO1, forkhead box protein O1; L-fluoxetine, 40 mg/kg fluoxetine; PEPCK, phosphoenolpyruvate carboxykinase; PI3K-AKT, phosphatidylinositol 3-kinase-protein kinase B; p-PI3K, phosphorylated PI3K; p-AKT, phosphorylated AKT; PPARγ, peroxisome proliferator-activated receptor γ.](MMR-22-04-3073-g04){#f5-mmr-22-04-3073}
